In the past weeks, we’ve reviewed four innovators at the forefront of cancer innovation:
Concarlo Holdings is developing a new drug to prevent cancer from becoming drug-resistant so that prescribed therapies are effective longer.
Raadysan is developing the first targeted therapy for triple-negative breast cancer.
Cancer University is building an online resource to inform cancer patients and caregivers on expectations and options.
fixNip is creating a 3D implant to provide breast reconstruction patients an option for a more natural nipple appearance.
Would you take a few minutes to watch the recap video below and let us know which of these is most important to support by clicking here to take our very short survey?